{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:10:04Z","timestamp":1770754204183,"version":"3.50.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00228-024-03689-3","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:01:26Z","timestamp":1712880086000},"page":"1141-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of dabigatran and rivaroxaban in atrial fibrillation patients with impaired liver function: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"80","author":[{"given":"Xinhai","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaowei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengfen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangsheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianxu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"6","key":"3689_CR1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10557-020-07065-y","volume":"35","author":"ZC Huang","year":"2021","unstructured":"Huang ZC, Li CQ, Liu XY et al (2021) Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Cardiovasc Drugs Ther 35(6):1205\u20131215","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"3689_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129(8):837\u2013847","journal-title":"Circulation"},{"issue":"3","key":"3689_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2459\/JCM.0b013e328358554b","volume":"15","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Curnis A, Latini MG et al (2014) Risk factors for atrial fibrillation recurrence: a literature review. J Cardiovasc Med (Hagerstown) 15(3):235\u2013253","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"3689_CR4","doi-asserted-by":"crossref","unstructured":"Joglar JA, Chung MK, Armbruster AL (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines [published correction appears in Circulation. 2024 Jan 2;149(1):e167] [published correction appears in Circulation. 2024 Feb 27;149(9):e936]. Circulation 149(1):e1\u2013e156","DOI":"10.1161\/CIR.0000000000001207"},{"issue":"6","key":"3689_CR5","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M et al (2022) Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics 14(6):1120 Published 2022 May 24","journal-title":"Pharmaceutics"},{"key":"3689_CR6","doi-asserted-by":"publisher","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","volume":"8","author":"X Gao","year":"2021","unstructured":"Gao X, Cai X, Yang Y et al (2021) Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 8:757087 Published 2021 Nov 22","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"3689_CR7","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","volume":"71","author":"A Qamar","year":"2018","unstructured":"Qamar A, Vaduganathan M, Greenberger NJ et al (2018) Oral anticoagulation in patients with liver disease. J Am Coll Cardiol 71(19):2162\u20132175","journal-title":"J Am Coll Cardiol"},{"key":"3689_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez\u2010Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"3689_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808","journal-title":"N Engl J Med"},{"key":"3689_CR11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR Buller","year":"2013","unstructured":"Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415","journal-title":"N Engl J Med"},{"issue":"10","key":"3689_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","volume":"147","author":"OD Lawal","year":"2023","unstructured":"Lawal OD, Aronow HD, Shobayo F et al (2023) Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study. Circulation 147(10):782\u2013794","journal-title":"Circulation"},{"key":"3689_CR13","doi-asserted-by":"crossref","unstructured":"Lau WCY, Torre CO, Man KKC et al (2022) Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study [published correction appears in Ann Intern Med. 2022;]. Ann Intern Med 175(11):1515\u20131524","DOI":"10.7326\/M22-0511"},{"issue":"1","key":"3689_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ehjcvp\/pvac063","volume":"9","author":"Y Talmor-Barkan","year":"2022","unstructured":"Talmor-Barkan Y, Yacovzada NS, Rossman H et al (2022) Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur Heart J Cardiovasc Pharmacother 9(1):26\u201337","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"3689_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","volume":"48","author":"Y Bai","year":"2017","unstructured":"Bai Y, Deng H, Shantsila A, Lip GY (2017) Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke 48(4):970\u2013976","journal-title":"Stroke"},{"issue":"15","key":"3689_CR16","doi-asserted-by":"publisher","first-page":"e009263","DOI":"10.1161\/JAHA.118.009263","volume":"7","author":"CL Wang","year":"2018","unstructured":"Wang CL, Wu VC, Kuo CF et al (2018) Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function: a retrospective cohort study. J Am Heart Assoc 7(15):e009263","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"3689_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365(2):147\u2013156. https:\/\/doi.org\/10.1056\/NEJMra1011170","journal-title":"N Engl J Med"},{"key":"3689_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/asheducation-2015.1.243","volume":"2015","author":"JL Kujovich","year":"2015","unstructured":"Kujovich JL (2015) Coagulopathy in liver disease: a balancing act. Hematol Am Soc Hematol Educ Program 2015:243\u2013249","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"3689_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272","journal-title":"Chest"},{"issue":"5","key":"3689_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest 138(5):1093\u20131100","journal-title":"Chest"},{"issue":"4","key":"3689_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"key":"3689_CR22","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med 361(12):1139\u20131151"},{"issue":"38","key":"3689_CR23","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, ESC Scientific Document Group et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"4","key":"3689_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen S, P\u00fcrerfellner H, Meyer C et al (2022) Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >\u200920 000 patients. Eur Heart J Cardiovasc Pharmacother 8(4):336\u2013345","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3689_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"3689_CR26","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ et al (2017) Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359","DOI":"10.1136\/bmj.j5058"},{"issue":"12","key":"3689_CR27","doi-asserted-by":"publisher","first-page":"e0144856","DOI":"10.1371\/journal.pone.0144856","volume":"10","author":"AT Cohen","year":"2015","unstructured":"Cohen AT, Hamilton M, Mitchell SA et al (2015) Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE 10(12):e0144856","journal-title":"PLoS ONE"},{"issue":"2","key":"3689_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","volume":"6","author":"OW Rutherford","year":"2020","unstructured":"Rutherford OW, Jonasson C, Ghanima W et al (2020) Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 6(2):75\u201385","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"3689_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/joim.12683","volume":"283","author":"L Staerk","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GYH et al (2018) Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 283(1):45\u201355","journal-title":"J Intern Med"},{"key":"3689_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2018.03.047","volume":"268","author":"NW Andersson","year":"2018","unstructured":"Andersson NW, Svanstr\u00f6m H, Lund M et al (2018) Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. Int J Cardiol 268:113\u2013119","journal-title":"Int J Cardiol"},{"issue":"2","key":"3689_CR31","first-page":"346","volume":"59","author":"RS Costache","year":"2023","unstructured":"Costache RS, Dragomiric\u0103 AS, Gheorghe BE et al (2023) Oral anticoagulation in patients with chronic liver disease. Med (Kaunas) 59(2):346","journal-title":"Med (Kaunas)"},{"issue":"10","key":"3689_CR32","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676","journal-title":"Europace"},{"issue":"1","key":"3689_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jpm9010007","volume":"9","author":"SH Kanuri","year":"2019","unstructured":"Kanuri SH, Kreutz RP (2019) Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 9(1):7","journal-title":"J Pers Med"},{"issue":"6","key":"3689_CR34","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M (2021) Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther 110(6):1526\u20131536","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03689-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:02:42Z","timestamp":1720162962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03689-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03689-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study complied with the Declaration of Helsinki and was authorized by The Ethics Committee of <i>Fujian Maternal and Child Health Hospital<\/i> on <i>January 19, 2023<\/i> (registration number: <i>ChiCTR2300067734<\/i>). Due to the retrospective nature of this study, the review board waived the informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}}]}}